Q1 Earnings Forecast for CRGX Issued By William Blair

CARGO Therapeutics, Inc. (NASDAQ:CRGX) – Analysts at William Blair issued their Q1 2025 earnings per share (EPS) estimates for shares of CARGO Therapeutics in a research note issued to investors on Monday, January 13th. William Blair analyst S. Corwin expects that the company will earn ($0.95) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for CARGO Therapeutics’ current full-year earnings is ($3.73) per share. William Blair also issued estimates for CARGO Therapeutics’ Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.95) EPS and Q4 2025 earnings at ($0.83) EPS.

A number of other brokerages have also commented on CRGX. Chardan Capital reissued a “buy” rating and set a $28.00 price target on shares of CARGO Therapeutics in a research note on Wednesday, November 13th. HC Wainwright restated a “buy” rating and issued a $33.00 price target on shares of CARGO Therapeutics in a research report on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $31.80.

CARGO Therapeutics Stock Down 7.1 %

CRGX opened at $11.18 on Wednesday. The company has a market capitalization of $514.59 million, a PE ratio of -2.62 and a beta of 2.50. The firm has a 50-day simple moving average of $16.10 and a two-hundred day simple moving average of $17.69. CARGO Therapeutics has a 52 week low of $10.91 and a 52 week high of $33.92.

CARGO Therapeutics (NASDAQ:CRGX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($1.14) by $0.26.

Institutional Trading of CARGO Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its position in CARGO Therapeutics by 87.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 295,960 shares of the company’s stock valued at $5,460,000 after acquiring an additional 138,261 shares during the last quarter. Geode Capital Management LLC grew its holdings in CARGO Therapeutics by 80.6% during the 3rd quarter. Geode Capital Management LLC now owns 838,279 shares of the company’s stock valued at $15,469,000 after purchasing an additional 374,018 shares during the last quarter. Barclays PLC grew its holdings in CARGO Therapeutics by 226.7% during the 3rd quarter. Barclays PLC now owns 56,354 shares of the company’s stock valued at $1,039,000 after purchasing an additional 39,102 shares during the last quarter. MetLife Investment Management LLC raised its position in CARGO Therapeutics by 59.3% in the 3rd quarter. MetLife Investment Management LLC now owns 19,833 shares of the company’s stock worth $366,000 after purchasing an additional 7,380 shares during the period. Finally, FMR LLC lifted its stake in CARGO Therapeutics by 1.1% in the third quarter. FMR LLC now owns 6,954,476 shares of the company’s stock worth $128,310,000 after purchasing an additional 77,508 shares during the last quarter. Hedge funds and other institutional investors own 93.16% of the company’s stock.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.